Wegovy and pancreatitis symptoms: recognising the signs and when to act

Step 1: Understand how semaglutide affects the pancreas

Semaglutide works by activating GLP-1 receptors involved in appetite regulation and glucose control. The pancreas is nearby in the abdomen and has its own GLP-1 receptors, which is thought to be one reason GLP-1 medicines carry a small but recognised risk of pancreatitis. The relationship is real enough that the MHRA specifically addressed it in a Drug Safety Update published on 29 January 2026, confirming acute pancreatitis as a known infrequent side effect of GLP-1 receptor agonists. You can read the NHS medicines guidance on Wegovy for a full picture of how the medicine works.

It is worth separating this clearly from the much more common gastrointestinal effects (nausea, loose stools, indigestion, belching) that many people notice in the first few weeks of treatment, especially after a dose increase. Those are expected, usually settle on their own, and are not signs of pancreatitis. The distinction matters because the two can feel superficially similar at first. Understanding what actually causes pancreatitis on Wegovy can help you stay alert to the right signals rather than worrying about every bout of indigestion.

The honest picture: pancreatitis is uncommon in people taking semaglutide. Most patients complete treatment without ever encountering it. But when it does occur, it can be serious, and the pattern of symptoms is specific enough to recognise.

Step 2: Know the specific warning signs

The symptom that distinguishes acute pancreatitis from ordinary digestive discomfort is pain. Not the mild nausea or stomach grumbling that often comes with starting a GLP-1 medicine, but a severe, persistent ache or cramping in the upper abdomen that does not ease off. In many cases it radiates toward the back or feels worse lying flat. It may come with vomiting, but the vomiting doesn't bring relief the way ordinary nausea might.

Other features to watch for include fever, a rapid pulse, loss of appetite that feels more pronounced than your usual reduced hunger on Wegovy, and tenderness when you press on the upper abdomen. The NHS medicines page for semaglutide lists the signs to look out for and advises stopping the medicine and seeking help if you suspect pancreatitis.

A useful mental test: if the abdominal pain is severe enough that you would hesitate to push through it and carry on with your day (the kind of pain that makes sitting still difficult) that is the threshold at which you should be picking up the phone rather than waiting to see if it passes. Mild stomach upset after a dose change is not in this category. Persistent, severe pain that radiates to the back is.

For a deeper look at the risk factors and what the clinical evidence shows, the page on whether Wegovy can give you pancreatitis covers this in detail.

Step 3: When to get medical help, and how to report it

If you develop severe or persistent abdominal pain while taking Wegovy, stop the injection and contact a doctor or NHS 111 the same day. Do not wait for your next routine appointment. If the pain is extreme, you feel very unwell, or symptoms escalate quickly, call 999 or go to A&E. Pancreatitis is diagnosed and treated in hospital, usually with imaging and blood tests; the earlier it is assessed, the better the outcome.

Tell the medical team you are on semaglutide. That single piece of information shapes which tests they run and how quickly. It is also important to tell your prescriber at nume, both so they can review whether to pause or stop treatment and so the event is documented in your care record. You can reach the team through our contact page, where aftercare support is available seven days a week.

Patients and carers can also report suspected side effects directly to the MHRA through the Yellow Card scheme. Reporting matters: it is how the MHRA tracks signals across thousands of prescriptions and updates its guidance. The January 2026 Drug Safety Update on pancreatitis was informed by exactly this kind of real-world reporting. If you think something went wrong with your medicine (including concerns about the supply) the Yellow Card scheme accepts those reports too.

Our prescribers discuss potential side effects, including the pancreatitis risk, as a standard part of the consultation. If you are considering Wegovy and want to understand your individual risk profile, check your eligibility and speak with a clinician before starting.

Step 4: How to reduce your risk going forward

There is no guaranteed way to prevent pancreatitis in someone taking a GLP-1 medicine, but a few things reduce the background risk. Alcohol significantly increases the general risk of pancreatitis independently of medication; drinking heavily while on Wegovy compounds the risk. Gallstones are another common trigger, and rapid weight loss can temporarily increase gallstone formation, so any new or worsening pain in the upper right abdomen is worth reporting to a doctor. A low-fat diet during treatment is sensible on both counts.

People with a history of pancreatitis, certain gallbladder conditions, or very high triglycerides are assessed more carefully at the consultation stage, because these factors sit alongside GLP-1 use as independent risk contributors. If any of these apply to you, mention them in your medical history when you complete the questionnaire — the prescriber reviewing your case will factor them in.

The steps you can take to reduce the pancreatitis risk on Wegovy are worth reading alongside this page, as are the broader practical tips for avoiding pancreatitis while on treatment. Neither replaces clinical advice, but both give you a clearer framework for the conversation with your prescriber. For common digestive side effects that are less urgent but still uncomfortable, the guidance on managing constipation on Wegovy is a practical starting point.